ClinicalTrials.gg
Active, not recruitingNCT06816108Updated Aug 5, 2026

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

A Phase 1 interventional study of ONO-7428 in Solid Tumor and NSCLC, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 15 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.

02

Conditions studied

  • Solid Tumor
  • NSCLC
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with or cytologically confirmed unresectable advanced or recurrent solid tumors.

    [Backfill cohort only] Participants with histologically or cytologically confirmed Stage IIIB, IIIC, IV, or recurrent NSCLC according to UICC-TNM classification.

  2. Participants who are or intolerant to standard therapy.
  3. Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody containing regimen.
  4. Participants with Performance Status 0 or 1.
  5. Participants with tumor tissue samples available for biomarker testing.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a complication or history of severe to any other antibody drugs.
  2. Participants with concurrent disease or a history of chronic or recurrent autoimmune disease
  3. Participants with severe peritoneal dissemination.
  4. Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.
  5. Participants with uncontrolled tumor-related pain.
  6. Participants with active or history of interstitial lung disease or pulmonary fibrosis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    ONO-7428

    Drug: ONO-7428

Interventions

  • DrugONO-7428

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities(DLT)

    Time frame: 21 days

  2. Adverse event (AE)

    Time frame: Up to 2 years

Secondary outcomes

  1. Cmax

    Time frame: Up to 2 years

  2. Tmax

    Time frame: Up to 2 years

  3. Area under the Plasma Concentration versus Time Curve (AUC)

    Time frame: Up to 2 years

  4. Ctrough

    Time frame: Up to 2 years

  5. Objective Response Rate (ORR)

    Time frame: Up to 2 years

  6. Disease Control Rate (DCR)

    Time frame: Up to 2 years

  7. Overall Survival (OS)

    Time frame: Up to 2 years

  8. Progression-Free Survival (PFS)

    Time frame: Up to 2 years

  9. Duration of Response (DOR)

    Time frame: Up to 2 years

  10. Time to Response (TTR)

    Time frame: Up to 2 years

  11. Best Overall Response (BOR)

    Time frame: Up to 2 years

  12. Percent change from baseline in the sum of diameters of target lesions

    Time frame: Up to 2 years

  13. Best reduction percent change from baseline in the sum of diameters of target lesions

    Time frame: Up to 2 years

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jul 2029, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 10, 2025
StartActual
Apr 21, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816108
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Apr 21, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Aug 5, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion